Bayer Pharma AG

Essence of this Article

Other antithrombotics such as atopaxar, dabigatran and TAK-442 have been investigated in phase II trials for the secondary prevention of acute coronary syndrome (ACS), but have not progressed to phase III trials because of disappointing results. Apixaban was investigated in a phase III trial but was associated with high rates of bleeding.

Investigational strategies

Other antithrombotics such as atopaxar, dabigatran, darexaban and TAK-442 have been investigated in phase II trials for the secondary prevention of ACS, but have not progressed to phase III trials because of disappointing results. Apixaban was investigated in a phase III trial but was associated with high rates of bleeding.


Where to next?